| Elucidation of the Hsp90 C-terminal inhibitor binding site RL Matts, A Dixit, LB Peterson, L Sun, S Voruganti, P Kalyanaraman, ... ACS chemical biology 6 (8), 800-807, 2011 | 118 | 2011 |
| The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors S Voruganti, JC LaCroix, CN Rogers, J Rogers, RL Matts, SD Hartson Journal of proteome research 12 (8), 3697-3706, 2013 | 30 | 2013 |
| Elucidation of the Hsp90 C-terminal inhibitor binding site, ACS Chem RL Matts, A Dixit, LB Peterson, L Sun, S Voruganti, P Kalyanaraman, ... Biol., Article ASAP, doi 10, 2011 | 15 | 2011 |
| Proteomic profiling of Hsp90 inhibitors S Voruganti, JT Kline, MJ Balch, J Rogers, RL Matts, SD Hartson Chaperones: Methods and Protocols, 139-162, 2018 | 12 | 2018 |
| A Detailed Protocol for Generation of Therapeutic Antibodies with Galactosylated Glycovariants at Laboratory Scale Using In-Vitro Glycoengineering Technology S Voruganti, J Xu, X Li, G Balakrishnan, SM Singh, SR Kar, TK Das Journal of Pharmaceutical Sciences 110 (2), 935-945, 2021 | 2 | 2021 |
| The proteomics fingerprints of AUY922 and 17-DMAG indicate common mechanisms of action for Hsp90 inhibitors S Voruganti Oklahoma State University, 2013 | | 2013 |
Robert MattsRegents and Sarkeys Distinguished Professor of Biochemistry and Molecular Biology, Oklahoma State UniversityVerified email at okstate.edu
